Categories Earnings, Health Care

Cancer drugs boost AstraZeneca results in Q1

Riding on the strong demand for its cancer drugs, AstraZeneca Plc (NYSE: AZN) on Friday reported its third consecutive quarter of top line growth. Product sales for the quarter jumped 14% to $5.46 billion, without taking into account the impact of currency fluctuations.

Product sales were primarily boosted by the oncology segment, where sales improved 59%, with particular strength in emerging markets including China.

AstraZeneca Product Sales Mix

Total revenue grew 11% to $5.49 billion, surpassing analysts’ projection of $5.27 billion. Core EPS doubled to 89 cents per share, beating the consensus estimate by 46 cents.

Lung Cancer drug Tagrisso was the best selling product during the quarter. Sale of this drug almost doubled to $630 million and accounted for 12% of its total product sales.

AstraZeneca product sales growth by segment

CEO Pascal Soriot said, “Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. In Oncology, Tagrisso, Imfinzi, and Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta, and Fasenra also grew strongly.”

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

“The recently-announced collaboration with Daiichi Sankyo also broadened an exciting Oncology portfolio with a potentially-transformative cancer treatment that could benefit patients around the world,” he added.

Outlook

The British-Swedish biopharmaceutical company revised its guidance following the solid results. The company now expects full-year 2019 product sales in a high single-digit percentage increase. Core EPS is projected in the range of $3.50 to $3.70.

AZN shares were down 1.4% during pre-market trading on Friday. The stock has gained 2.6% in the year-to-date period.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

AVGO Earnings: Broadcom Q2 2024 revenue and profit beat estimates

Semiconductor company Broadcom, Inc. (NASDAQ: AVGO) on Wednesday reported higher second-quarter revenues and adjusted earnings. The results also topped analysts' expectations. Earnings, excluding non-recurring items, came in at $10.96 per

Key takeaways from Oracle’s (ORCL) Q4 2024 earnings report

Oracle Corporation’s (NYSE: ORCL) stock rallied this week after the company announced large cloud infrastructure deals with tech giants Google, OpenAI, and Microsoft. The demand for Oracle's generative AI infrastructure

ZDGE Earnings: Zedge reports higher revenues and adj. profit for Q3 2024

Content distribution platform Zedge, Inc. (NYSE American: ZDGE) has reported higher net income for the third quarter of 2024, on an adjusted basis. The bottom line benefitted from a double-digit

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top